Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma.
about
Wnt signaling in B-cell neoplasiaAn unusual H-Ras mutant isolated from a human multiple myeloma line leads to transformation and factor-independent cell growth.Cancer stem cells: controversies in multiple myelomaT cells induce terminal differentiation of transformed B cells to mature plasma cell tumors.The role of adhesion molecules in multiple myeloma.Bone marrow microenvironment and the progression of multiple myeloma.Disruption by interferon-alpha of an autocrine interleukin-6 growth loop in IL-6-dependent U266 myeloma cells by homologous and heterologous down-regulation of the IL-6 receptor alpha- and beta-chains.The role of interleukin-3 in classical Hodgkin's disease.Targeting signalling pathways for the treatment of multiple myeloma.Mouse plasmacytoma growth in vivo: enhancement by interleukin 6 (IL-6) and inhibition by antibodies directed against IL-6 or its receptor.The bone marrow of multiple myeloma patients contains B cell populations at different stages of differentiation that are clonally related to the malignant plasma cellInterleukin 6 is essential for in vivo development of B lineage neoplasms.Interleukin-6 and the acute phase response.Cancer stem cells in multiple myeloma.The role of the insulin-like growth factor 1 receptor axis in multiple myeloma.Malignant B-cell intra-clonal diversification: following the yarn in the labyrinth.Cancer stem cells of differentiated B-cell malignancies: models and consequences.Fact or fiction--identifying the elusive multiple myeloma stem cell.N- and K-ras oncogenes in plasma cell dyscrasias.The involvement of adhesion molecules in the biology of multiple myeloma.Interleukin-3: structure and function.Modulation of interleukin-6/interleukin-6 receptor cytokine loop in the treatment of multiple myeloma.Anti-myeloma activity of MELK inhibitor OTS167: effects on drug-resistant myeloma cells and putative myeloma stem cell replenishment of malignant plasma cells.C-kit ligand (SCF) in human multiple myeloma cells.Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines.Constituents of autocrine IL-6 loops in myeloma cell lines and their targeting for suppression of neoplastic growth by antibody strategies.Expression and functional role of c-kit ligand (SCF) in human multiple myeloma cells.Up-regulation of IL-6-receptors by IL-3 on a plasma cell leukaemia cell line which proliferates dependently on both IL-3 and IL-6.Establishment and characterization of a plasma cell leukaemia cell line dependent for growth on IL-6 and a bi-phenotypic subclone dependent upon both IL-3 and IL-6.Selection and transplantation of autologous hematopoietic CD34+ cells for patients with multiple myeloma.Secretory IgA in saliva can be a useful stress marker.Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cellsEvidence for a bone marrow B cell transcribing malignant plasma cell VDJ joined to C mu sequence in immunoglobulin (IgG)- and IgA-secreting multiple myelomas.Expression of adhesion molecules on myeloma cells.Clonal rearrangement of immunoglobulin genes in the peripheral blood of multiple myeloma patients.Myeloma interacts with the bone marrow microenvironment to induce osteoclastogenesis and is dependent on osteoclast activity.Functional granulocyte/macrophage colony stimulating factor receptor is constitutively expressed on neoplastic plasma cells and mediates tumour cell longevity.Primary extranodal non-Hodgkin's lymphoma in adults: clinicopathological and survival characteristics.PI3-K/AKT/FKHR and MAPK signaling cascades are redundantly stimulated by a variety of cytokines and contribute independently to proliferation and survival of multiple myeloma cells.Hematologic neoplasias and acromegaly.
P2860
Q28182311-B1EF22B0-23BA-4421-838E-AF2019E040C4Q30885275-F70BF8DB-4AD8-41CF-AD65-CA1941ED76E4Q34462722-ABA33B32-8A75-40B5-84D6-7338B061405AQ34712334-3FDEE9F7-C502-44F8-94D6-903B3215C841Q35663030-774A42E2-A067-4603-8D50-5E55ACAF7D68Q35664731-469161CC-D983-4922-8AE5-C0F79E51695EQ35824530-521EE5A8-DA5F-4762-AE44-F638196526DCQ35994955-B9314FCC-9C90-49EB-8689-2D2213BCF627Q36150866-31BF42C8-DDA7-4295-8A52-9F719CA9E67CQ36353435-31F77955-34CD-40C7-B8C6-98F942EBE8E8Q36362222-1AB51450-1CD6-41FF-A7E5-D5E642118F53Q36365082-4787AC11-0DC3-403C-8A57-3FEE051E9CB5Q36559880-D597EE42-86E2-41B1-9C5D-DA424C92CDA7Q37133709-E14775C1-CA60-47D5-BC7F-B96A18753506Q37398728-9BBD0F2E-9F3A-4FAE-A1D1-76779AEC24FDQ37894085-C46B1D73-AD38-4C44-A60A-638465EC5392Q38161351-DC38272D-25C4-46BD-AF2F-8CD29DB45882Q38169258-71DDC785-B2DB-4C14-B7C3-D8C5BF490552Q40594604-34DD27DE-32EE-434A-80DB-07D69A1EBBECQ40828957-0201DB7D-643B-419D-9584-77E8799C1614Q40860967-809F2C8B-EECA-464B-A3F2-024E836CE225Q40875040-6B66C7E0-6BA6-4B0A-ADCF-2875CB6677B7Q41085328-9F538431-1D41-4087-A104-DD2C701D1297Q41132563-47DB3648-7D6A-492C-A59A-A9376F9FA0B2Q41208928-3E131FDC-5D38-436D-B570-762D3C3310FFQ41229156-B3263A1D-E8FB-4F0B-81B1-772E74FD5BA0Q41426280-1855C77B-6377-49A0-B1DE-A1C802B9B4BDQ41560773-145FEFF7-60E2-476F-9F71-9DC7C9B940D4Q41680276-C223A08F-87F3-4922-85C0-5821C63BE102Q41756670-E1B15D60-A220-4768-8796-21865AEF4979Q41788738-4C011E79-AA7B-44C0-86E1-CA4831DCC43BQ42007014-D1D251FB-B57F-4B46-976B-DFF491F66470Q42614266-0AED4A88-FF1B-4D49-B52A-FC7B73B47E98Q42812567-7A091602-FF59-46F2-9F87-E6ED11E10888Q43490719-87685593-CD8F-4DAE-857C-647F40517499Q43883711-92E2414D-4D8C-4C0F-B71F-A46F43C38272Q50110311-4CBDDEEB-B1B8-430E-8467-A338FEC23BF0Q50994246-A0221C29-FF45-4757-9EDE-7A3C4B59008CQ52942846-67311630-F711-4EB0-B9E2-A458333EAEC4Q53403062-916CF7A1-9ABF-4C67-9E32-CC9F9A381D36
P2860
Interleukin 3 and interleukin 6 synergistically promote the proliferation and differentiation of malignant plasma cell precursors in multiple myeloma.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年論文
@yue
1989年論文
@zh-hant
1989年論文
@zh-hk
1989年論文
@zh-mo
1989年論文
@zh-tw
1989年论文
@wuu
1989年论文
@zh
1989年论文
@zh-cn
name
Interleukin 3 and interleukin ...... recursors in multiple myeloma.
@en
Interleukin 3 and interleukin ...... recursors in multiple myeloma.
@nl
type
label
Interleukin 3 and interleukin ...... recursors in multiple myeloma.
@en
Interleukin 3 and interleukin ...... recursors in multiple myeloma.
@nl
prefLabel
Interleukin 3 and interleukin ...... recursors in multiple myeloma.
@en
Interleukin 3 and interleukin ...... recursors in multiple myeloma.
@nl
P2093
P2860
P356
P1476
Interleukin 3 and interleukin ...... recursors in multiple myeloma.
@en
P2093
Caligaris-Cappio F
P2860
P304
P356
10.1084/JEM.170.2.613
P407
P577
1989-08-01T00:00:00Z